Clinical laboratory must use only validated measurement procedures for a determined need. Precision is one of the most important characteristics for selection, incorporation, validation and verification of a measurement procedure.
Background-aim
Clinical laboratory must use only validated measurement procedures for a determined need. Precision is one of the most important characteristics for selection, incorporation, validation and verification of a measurement procedure.
Our goal was to verify the precision performances declared by the manufacturer for a new measurement procedure used in our laboratory in order to determine the N-terminal pro-brain natriuretic peptide (NT-proBNP).
Methods
The NT-proBNP was analyzed using a CENTAURO XP® (Siemens Healthineers) by chemiluminescent immunometric assay.
Samples used in the study were comercial control materials from BioRad® (Liquichek Cardiac Markers Plus Control) .
A value of 168 pg/mL was used as a control 1, and another value of 5428 pg/mL as a control 3.
Three replicates of each level of control was analyzed for 5 days. Intraserial precision and laboratory precision were calculated using standard deviation and average. The obtained values were compared with the provided specifications by the manufacturer for precision.
Results
For control 1, we obtained a 5% intraserial precision, and a 6% laboratory precision, and for control 3 we obtained a 2% intraserial precision, and a 3% laboratory precision.
Imprecision data provided by the manufacturer were: for control 1, 5% intraserial precision, and 8% laboratory precision; for control 3, 7% intraserial precision, and 10% laboratory precision.
Conclusions
Values obtained for intraserial precision and laboratory precision are lower to those provided by the manufacturer. We concluded that the provided specifications by the manufacturer are verified for precision, and that they are suitable for the expected use, being always in the same conditions for calibration frequency, users, reagents and calibrator batchs.
It is necessary a daily monitoring of imprecision using an internal quality control, to verify that established specifications are being followed. 
Background-aim
Objective. To evaluate the effect of EMR (1800 MHz) and biological efficacy of Acetyl-l-carnitine (ALCAR) on the programmed death of rat sperm.
Model. In experiment were used male rats (line Vistar) at the age of 1.5 months. Animals received ALCAR (7 mg/kg; 3 times in week) during period of EMR exposure (30 days) in the range of mobile communications 1800 MHz. Material was taken on the 1st and 30th days after exposure.
Experimental groups. Each group consisted of 8 animals:
• Negative control (group 1); • Positive control: animals EMR exposed (group 2);
• ALCAR: animals EMR exposed and received ALCAR (group 3).
Methods
Studied indicators: early apoptosis, late apoptosis and necrosis of spermatozoa. The method of flow-cytometry was performed using Annexin V-FITC and Propidium iodide. Equipment: Beckman Coulter FC 500 cytometer.
Results
On the 1st day after exposure of EMR there was an increase in all the studied parameters. Especially high rate of late apoptosis in group 3: 327.27% (relative to group 1) and 52.27% (relative to group 2). On the 30th day the indices of early and late apoptosis significantly increased in the 3rd group by 366.67% (relative to the 0009-8981/$ -see front matter Clinica Chimica Acta 493 (2019) S730-S732
Contents lists available at SciVerse ScienceDirect Clinica Chimica Acta j o u r n a l h o m e p a g e : w w w. e l s e v i e r. c o m / l o c a t e / c l i n c h i m 1st group). However, there was a decrease in indicators relative to group 2 by 30.77% and 19.51%, respectively. Cell necrosis rate is also reduced (by 8.93%) relative to group 2. The number of necrotic sperm on the 1st day after exposure to EMR significantly increased by 34.80% in group 2 and 54.80% in group 3 relative to the control group 1. 
Conclusions

Background-aim
Gene synaptotagmin 1 (SYT1 human, murine Syt1) encodes a protein that fuses vesicles to the neural membrane but it's functions in the liver are rather unknown.
The aim of this study is to clone Syt1 murine gene and overexpress it in HepG2 cell culture and in wild type mouse from the lineage C57BL/6 J.
Methods
The plasmid pLIVElucSyt1 was designed with a liver tissue promoter of high affinity, a gene for resistance to kanamycin, a coding region of luciferase to assess whether if cell culture or animals models expresses plasmid and the gene Syt1.
After obtaining the pLIVElucSyt1 plasmid and bacterial transformation the recombination, cloning and transformation of bacteria were assessed with an analysis of coils and supercoils, a PCR for exon 7-8 of Syt1 and with restriction enzymes. Then Syt1 was sent for sequencing.
HepG2 cells were sown with maintenance growth medium. Syt1 expression was examined by luciferase luminescence, mRNA (messenger ribonucleic acid) expression and complementary DNA (cDNA) analysis.
14 mouse wild type from the lineage C57BL/6J were used in the study. They were transfected with a hydrodinamic inyection and assessed the plasmid in vivo with fluorescence. To verify the expression of Syt1 in the models mRNA expression analysis and complementary DNA (cDNA) obtained with quantitative polymerase chain reaction (qPCR) analysis was made.
Results
Syt1 sequence was studied with NCBI's BLAST obtaining a query cover of 99% and an identity of 95% with Syt1 in Mus musculus.
HepG2 cells transfection was assessed in the spectrophotometer giving more fluorescence than the non transfected cells and was confirmed with the cDNA obtained, the transfected cells presented a more marked band in the electrophoresis.
Animal model transfection was assessed by fluorescence and with comparison in the amount of cDNA being both statistically higher in the transfected animals p b 0,05.
Conclusions
1 pLIVElucSyt1 provides satisfactory entry in hepatic tissue, cloning and transfection.
2 The adding of encoded luciferase permits assessment of plasmid function prior to collection sample.
3 Hepatocytes express Syt1 physiologically and the procedure described managed to produce an overexpression of the gene which could be used for further investigations. 
Background-aim
Antibody fragments, such as Fab fragments, are widely used in diagnostics, basic life sciences research and increasingly in therapeutic applications as well. Regarding diagnostic assays, the Fab fragment has several advantages over full-length IgGs, like reduced interference in IVD assays due to the lack of Fc part and better coating density. Furthermore, the Fabs can be readily produced in E. coli and thus the Fabs are compatible with phage display. However, expression levels of the Fabs often are quite low and production of the Fabs can induce toxic effects in host organism, including E. coli. It is known that the expression levels and host organism viability can be drastically affected by modulation of codon usage. We had a Fab fragment that was lethal to E. coli and therefore couldn't be expressed. We sought to restore the viability of the host and thus its expression capability by modulating the codon usage of PelB signal sequence of the Fab.
Methods
We established two PelB signal sequence libraries that included changes only in codon usage (synonymous mutations). One library included changes in the N part of the PelB and another in the hydrophobic part of the PelB. Then, we cloned codon usage modulated heavy chain PelB signal sequences from the library into the lethal Fab, plated the cloning reactions, picked the viable clones from the plate and cultivated the viable clones in 5 ml cultures in order to produce Fab fragment.
Results
We obtained several viable clones by modulating the codon usage of the heavy chain of the PelB signal sequence. Moreover, we identified clones that yielded up to 0.9 μg/ml of immunoreactive Fab fragment just after 3 h of induction.
Conclusions
We show that a library containing synonymous mutations in the PelB signal sequences is an efficient tool to alleviate the toxic effects of Fab fragment and to increase the expression levels. Furthermore, the utilization of the library is not restricted to the Fab in question but can be readily applied to any Fab or secreted molecule in E. coli. 
Background-aim
Sarcoidosis is a multisystem granulomatous disease, whose unpredictable course has prompted research into biomarkers useful to predict outcome. Chitotriosidase, a chitinase produced by activated macrophages, has recently been proposed as an indicator among the potential markers of sarcoidosis. Increased macrophage activity is also present in tuberculosis. The aims of this study were to evaluate value of chitotriosidase as a marker of sarcoidosis, as well as applicability of it in the diagnosis of tuberculosis.
Methods
217 biopsy positive sarcoidosis patients were analyzed. 80pa-tients had acute sarcoidosis (duration b2 years), 137 patients were with chronic sarcoidosis (duration longer than 2 years). At the time of the study 105 patients had symptoms and signs of active disease, 57patients experienced reactivation of sarcoidosis and 29 patients experienced relapse of chronic disease. 71 patients had a proven active pulmonary tuberculosis. Chitotriosidase activity in serum of patients and 264 healthy controls was determined using the spectrofluorometric method with fluorogenic substrate 4-methylumbelliferyl-®-D-N-N′-N″-triacetylchitotrioside.
Results
Sensitivity of chitotriosidase in patients with clinical signs of active sarcoidosis is 76.8%, while the reliability of chitotriosidase to exclude the disease activity in patients without clinical signs of diseases activity (specificity) was 90.4% (cut off 159.9 nmol/mL/h). Logistic regression confirmed that patients with high serum chitotriosidase had likelihood of active disease comparing to patients with low serum chitotriosidase (odds ratio = 18.06; Confidence Interval for odds ratio from 7.24 to 45.03; p b .001). Logistic regression (classification of 88%) in groups active/not active sarcoidosis revealed the sensitivity for serum chitotriosidase test of 90.1% and specificity of 87.6%; (+) PV (predictive value) =88.6 and (−) PV = 89.3. Patients with tuberculosis had significantly lower values of chitotriosidase than patients with sarcoidosis (p = .000).
Conclusions
This recent study strongly supported the hypothesis that serum chitotriosidase could be a marker of sarcoidosis activity and severity. 
Background-aim
Endogenous opioids are neuropeptides involved in the painrelieving processes. In the peripheral nervous system (PNS) endogenous opioid peptides induce analgesia via binding to the related opioid receptors. This cause the cascade of interactions leading to inhibition of releasing the substances involved in the pain transmission eg. substance P. In the periphery they are synthesized and stored in cells of the immune system.
In the current study, we describe the fluctuations of endogenous opioids concentrations in the postoperative period in children in regarding multimodal anesthesia.
Methods
Forty-four children undergoing major spinal surgery were enrolled in the cohort study. They were divided into two groups: They were divided into two groups: group A (n = 21) generally anesthetized with rocuronium, fentanyl, morphine, propofol, dexamethasone, acetaminophen and a mixture of oxygen/air/sevoflurane and group B (n = 23) where in addition to the above-described anesthesia patients' were given i.v. lidocaine as a co-analgesic. We also recruited 20 healthy age-and gender-matched children (control group, CG). We measured endogenous opioids levels in serum using immunoenzymatic methods. We evaluated postoperative pain intensity using numerical or visual pain scale.
Results
The levels of measured endogenous opioids were similar in control and in studied groups before surgery. We noted that group B patients had lower pain intensity when compared to the group A subjects. In group B, the elevated serum concentration of ®-endorphin, enkephalin and dynorphin in the postoperative period were noted. We also reported that the area under the curve of the levels of endogenous opioids was negatively correlated with summary postoperative morphine dose. Finally, we noted positive correlation between lidocaine concentration and endoopioids levels.
Conclusions
Multidrug pain management including lidocaine seems to be more efficient than models without lidocaine. The endogenous opioid system should be considered as a novel target for pain relief therapy in children. doi:10.1016/j.cca.2019.03.1344 
